{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T12:52:40Z","timestamp":1711457560218},"reference-count":35,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSO"],"published-print":{"date-parts":[[2022,3,21]]},"abstract":"<jats:p>Aim: To present the case of a patient with myopic choroidal neovascular membrane (mCNV) in the 3rd trimester of pregnancy, who was treated with intravitreal ranibizumab.\n\nCase Report: The 34-year-old patient was referred to the Department of Ophthalmology of the University Hospital Kralovske Vinohrady in January 2020 for mCNV on her right eye (RE). The patient was in the 34th week of pregnancy. Initial best corrected visual acuity (BCVA) was 68 ETDRS letters. Spherical equivalent of the RE was -11.5 dioptres, axial length of the RE was 27.7 mm. Pigmented CNV with small haemorrhage was present on the retina of the RE. Optical coherence tomography (OCT) of the RE showed a hyperreflective mass above the retinal pigment epithelium, central retinal thickness (CRT) was 310 \u00b5m. OCT angiography confirmed the presence of a classic CNV in the macula of the RE. Two weeks later, the hyperreflective lesion and oedema in the macula of the RE increased, the CRT was 329 \u00b5m, BCVA remained stable. After discussion with the patient and the treating gynaecologist, intravitreal ranibizumab was administered in the RE in the 36th week of pregnancy. On check-up 3 weeks later, we observed the decrease of macular oedema to 276 \u00b5m and the improvement of BCVA to 78 ETDRS letters. The patient delivered a healthy baby girl in the 39th week of pregnancy via caesarean section, postnatal adaptation of the newborn was normal. During further visits, the BCVA improved to 83 ETDRS letters and the macular oedema disappeared completely. 8 months after the first ranibizumab injection, the CNV reactivated, BCVA decreased to 72 ETDRS letters, oedema was present in the macula and the CRT was 309 \u00b5m. Another ranibizumab was administered into the RE. The patient then discovered that she was pregnant; according to calculations, she was in the 3rd week of pregnancy at the time of the second ranibizumab injection. After the second injection, BCVA improved to 79 ETDRS letters, macular oedema on the OCT disappeared and CRT decreased to 264 \u00b5m. The pregnancy was terminated per patient\u2019s request.\n\nConclusion: Intravitreal administration of ranibizumab in the 3rd trimester of pregnancy led to the improvement of BCVA and decrease of macular oedema in the patient with mCNV. The injection had no adverse effect on the pregnancy or the postnatal adaptation of the newborn. However, it is always necessary to consider the risk\/benefit ratio when administering intravitreal antiVEGF drugs in pregnant patients. Thorough discussion with the patient is necessary.<\/jats:p>","DOI":"10.31348\/2022\/11","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:45:03Z","timestamp":1657802703000},"page":"79-83","source":"Crossref","is-referenced-by-count":1,"title":["Intravitreal Ranibizumab in Pregnant Patient with Myopic Choroidal Neovascular Membrane. A Case Report"],"prefix":"10.31348","volume":"78","author":[{"given":"Martin","family":"Pen\u010d\u00e1k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.e5. doi:10.1016\/j.ophtha.2008.10.018","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"ref1","unstructured":"Dole\u017ealov\u00e1 J, Karel I, Hallov\u00e1 H. Na\u0161e dvoulet\u00e9 zku\u0161enosti s l\u00e9\u010dbou vlhk\u00e9 formy v\u011bkem podm\u00edn\u011bn\u00e9 makul\u00e1rn\u00ed degenerace bevacizumabem (Avastin) [Our Two-Years Experience with the Bevacizumab (Avastin) Treatment of the Age Related Macular Degeneration Wet Form]. Cesk Slov Oftalmol. 2010;66(1):10-14. Czech."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Klime\u0161ov\u00e1 YM, Pen\u010d\u00e1k M, Stra\u0148\u00e1k Z, Lalinsk\u00e1 L, Veith M. One-Year Follow-up Outcomes of Treatment of Wet Age-Related Macular Degeneration with Aflibercept. Cesk Slov Oftalmol. 2018;74(2):47-52. doi:10.31348\/2018\/1\/1-2-2018","DOI":"10.31348\/2018\/1\/1-2-2018"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Stepanov A, Nemcansky J, Veith M, et al. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic. Eur J Ophthalmol. 2020. doi:10.1177\/1120672120971190","DOI":"10.1177\/1120672120971190"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology. 2015;122(6):1220-1227. doi:10.1016\/j.ophtha.2015.01.025","DOI":"10.1016\/j.ophtha.2015.08.045"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Stepanov A, Pencak M, Nemcansky J, et al. Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye. J Ophthalmol. 2020. doi:10.1155\/2020\/3076596","DOI":"10.1155\/2020\/3076596"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: A Randomized Controlled Study of Ranibizumab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia. Ophthalmology. 2014;121(3):682-692.e2. doi:10.1016\/j.ophtha.2013.10.023","DOI":"10.1016\/j.ophtha.2013.10.023"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;38(8):1464-1477. doi:10.1097\/IAE.0000000000001744","DOI":"10.1097\/iae.0000000000001744"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Stepanov A, St\u0159edov\u00e1 M, Dusov\u00e1 J, Jir\u00e1skov\u00e1 N, Studni\u010dka J. Ranibizumab for the treatment of choroidal neovascularization due to cause other than age related macular degeneration. Cesk Slov Oftalmol. 2019;75(3):138-144. doi:10.31348\/2019\/3\/4","DOI":"10.31348\/2019\/3\/4"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Brown DM, Heier JS, Clark WL, et al. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. Am J Ophthalmol. 2013;155(3):429-437.e7. doi:10.1016\/j.ajo.2012.09.026","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Korobelnik J-F, Holz FG, Roider J, et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014;121(1):202-208. doi:10.1016\/j.ophtha.2013.08.012","DOI":"10.3410\/f.718129981.793486311"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lalinsk\u00e1 L, Kr\u00e1sn\u00fd J, Studen\u00fd P, Veith M. Results of the first 12 months treatment of macular edema complicating BRVO in patients treated with ranibizumab. Cesk Slov Oftalmol. 2018;74(2):62-67. doi: 10.31348\/2018\/1\/3-2-2018","DOI":"10.31348\/2018\/1\/3-2-2018"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015;314(20):2137-2146. doi: 10.1001\/jama.2015.15217","DOI":"10.1001\/jamaophthalmol.2017.0837"},{"key":"ref13","unstructured":"St\u00e1tn\u00ed \u00fastav pro kontrolu l\u00e9\u010div. Avastin - Souhrn \u00fadaj\u016f o p\u0159\u00edpravku. 2005. Available from: https:\/\/www.sukl.cz\/modules\/medication\/detail.php?code=0028397&tab=texts"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Neelam K, Cheung CMG, Ohno-Matsui K, Lai TYY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495-525. doi: 10.1016\/j.preteyeres.2012.04.001","DOI":"10.1016\/j.preteyeres.2012.04.001"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Miyata M, Ooto S, Hata M, et al. Detection of Myopic Choroidal Neovascularization Using Optical Coherence Tomography Angiography. Am J Ophthalmol. 2016;165:108-114. doi: 10.1016\/j.ajo.2016.03.009","DOI":"10.1016\/j.ajo.2016.03.009"},{"key":"ref16","unstructured":"Akkaya S. Early Miscarriage Occurring Six Days After Intravitreal Ranibizumab Injection. Med Hypothesis Discov Innov Ophthalmol. 2019;8(2):69-72."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Fossum P, Couret C, Briend B, Weber M, Lagarce L. Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases. Eye (Lond). 2018;32(4):830-832. doi: 10.1038\/eye.2017.305","DOI":"10.1038\/eye.2017.305"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Jouve L, Akesbi J, Nordmann JP. Safety and efficacy of ranibizumab for pregnant women in idiopathic choroidal neovascularization. Acta Ophthalmol. 2015;93(7):e597-e598. doi: 10.1111\/aos.12611","DOI":"10.1111\/aos.12611"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sarhianaki A, Katsimpris A, Petropoulos IK, Livieratou A, Theoulakis PE, Katsimpris JM. Intravitreal administration of ranibizumab for idiopathic choroidal neovascularization in a pregnant woman. Klin Monbl Augenheilkd. 2012;229(4):451-453. doi: 10.1055\/s-0031-1299207","DOI":"10.1055\/s-0031-1299207"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"G\u00f3mez Ledesma I, de Santiago Rodriguez M\u00c1, Follana Neira I, Le\u00f3n Garrigosa F. Neovascular membrane and pregnancy. Treatment with bevacizumab. Arch Soc Esp Oftalmol (English Edition). 2012;87(9):297-300. doi: 10.1016\/j.oftal.2011.09.011","DOI":"10.1016\/j.oftale.2011.09.006"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Kianersi F, Ghanbari H, Naderi Beni Z, Naderi Beni A. Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy. Invest New Drugs. 2016;34(5):650-653. doi: 10.1007\/s10637-016-0361-8","DOI":"10.1007\/s10637-016-0361-8"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88(4):e136-e136. doi: 10.1111\/j.1755-3768.2009.01572.x","DOI":"10.1111\/j.1755-3768.2009.01572.x"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ammon Avalos L, Galindo C, Li DK. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol. 2012;94(6):417-423. doi: 10.1002\/bdra.23014","DOI":"10.1002\/bdra.23014"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Sullivan L, Kelly SP, Glenn A, Williams CPR, McKibbin M. Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond). 2014;28(4):492-494. doi: 10.1038\/eye.2013.311","DOI":"10.1038\/eye.2013.311"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"H\u00e5rd A-L, Hellstr\u00f6m A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment \u2013 a review. Acta Paediatr. 2011;100(12):1523-1527. doi: 10.1111\/j.1651-2227.2011.02445.x","DOI":"10.1111\/j.1651-2227.2011.02445.x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Cheung C. Vascular endothelial growth factor: possible role in fetal development and placental function. J Soc Gynecol Investig. 1997;4(4):169-177.","DOI":"10.1016\/s1071-5576(97)00025-7"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Vuorela P, Carp\u00e9n O, Tulppala M, Halmesm\u00e4ki E. VEGF, its receptors and the Tie receptors in recurrent miscarriage. Mol Hum Reprod. 2000;6(3):276-282. doi: 10.1093\/molehr\/6.3.276","DOI":"10.1093\/molehr\/6.3.276"},{"key":"ref28","unstructured":"St\u00e1tn\u00ed \u00fastav pro kontrolu l\u00e9\u010div. Lucentis \u2013 souhrn \u00fadaj\u016f o p\u0159\u00edpravku. 2018. Available from: https:\/\/www.sukl.cz\/modules\/medication\/detail.php?code=0194569&tab=texts."},{"key":"ref29","unstructured":"Bamdad S, Bamdad M, Khanlari M, Daneshbod Y, Khademi B. Teratogenic Effects of Intravitreal Injection of Bevacizumab in a Pregnant Rat Model. Iran J Pharm Res. 2017;16(2):670-676."},{"key":"ref30","unstructured":"St\u00e1tn\u00ed \u00fastav pro kontrolu l\u00e9\u010div. Eylea \u2013 souhrn \u00fadaj\u016f o p\u0159\u00edpravku. 2020. Available from: https:\/\/www.sukl.cz\/modules\/medication\/detail.php?code=0193696&tab=texts"},{"key":"ref31","unstructured":"St\u00e1tn\u00ed \u00fastav pro kontrolu l\u00e9\u010div. Beovu \u2013 souhrn \u00fadaj\u016f o p\u0159\u00edpravku. 2021. Available from: https:\/\/www.sukl.cz\/modules\/medication\/detail.php?code=0238813&tab=texts."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Landau D, Seelenfreund MH, Tadmor O, Silverstone BZ, Diamant Y. The effect of normal childbirth on eyes with abnormalities predisposing to rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1995;233(9):598-600. doi: 10.1007\/BF00404712","DOI":"10.1007\/bf00404712"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Neri A, Grausbord R, Kremer I, Ovadia J, Treister G. The management of labor in high myopic patients. Eur J Obstet Gynecol Reprod Biol. 1985;19(5):277-279. doi: 10.1016\/0028-2243(85)90041-3","DOI":"10.1016\/0028-2243(85)90041-3"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Eneh A, Almeida D. Valsalva hemorrhagic retinopathy during labour: a case report and literature review. Can J Ophthalmol. 2013;48(6):e145-e147. doi: 10.1016\/j.jcjo.2013.05.019","DOI":"10.1016\/j.jcjo.2013.05.019"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:45:09Z","timestamp":1657802709000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,21]]},"published-print":{"date-parts":[[2022,3,21]]}},"URL":"https:\/\/doi.org\/10.31348\/2022\/11","relation":{},"ISSN":["1805-4447","1211-9059"],"issn-type":[{"value":"1805-4447","type":"electronic"},{"value":"1211-9059","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}